A Food and Drug Administration panel unanimously recommended approval for a treatment that "genetically alters a patient's own cells to fight leukemia," turning them into what is being called "a living drug" to help stop the disease, according to The New York Times ("F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment"). The recommendation came down Wednesday and is likely to be accepted by the F.D.A.
The treatment, which will be the "the first gene therapy ever to reach the market," is expected to be followed by other gene therapies. Novartis is expected to be the first to drug company to market a "living drug" with its treatment for a type of leukemia. Drug companies and researchers "have been engaged in intense competition for decades to reach this milestone."
To read the Times article in its entirety, click here.
No comments:
Post a Comment